Doetsch Grether has received valuation services

Located in the heart of Basel, Switzerland, Doetsch Grether AG is a medium-sized, family-owned company with traditional values that specializes in the marketing and distribution of products in the pharma, OTC and consumer care segments.

Doetsch Grether’s portfolio consists of its own brands, such as the famous Grether’s Pastilles®, neo-angin® and Sulgan®N, as well as distribution brands that include Magnesium-Diasporal®, Tiger Balm® and Pearl Drops®, which are successfully sold throughout Switzerland.

Oaklins’ team in Switzerland has repeatedly advised Doetsch Grether on valuation topics, contract drafting and the preparation of second opinions in connection with various acquisition projects.

Service

Corporate finance services

Parties

“We consider Oaklins to be a very reliable and flexible partner who has always supported us competently and in a goal-oriented manner, even in hectic situations. Oaklins has been an important sparring partner for us in various projects.”

Lukas Grimm

CFO, Doetsch Grether AG

Talk to the deal team

Jens Rutten

Partner

Zurich, Switzerland
Oaklins Switzerland

View profile Get in touch

Related deals

HD Clinical Ltd. has been acquired by NEXUS AG

Healthcare | TMT

HD Clinical Ltd. has been acquired by NEXUS AG

NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.

Learn more

Reed Veterinary Surgery has been acquired by Kin Vet Community

Private Equity | Healthcare

Reed Veterinary Surgery has been acquired by Kin Vet Community

The acquisition of Reed Veterinary Surgery by Kin Vet Community has been successfully completed. Through this acquisition, the surgery joins a community of veterinary clinics where colleagues share knowledge and best practices to improve the wellbeing of their clients and their animals.

Learn more

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

Healthcare

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.

Learn more